Psychiatry Group Proposed Biomarker-Guided Drug Trials

A new position paper outlines a strategy to use biological signals to better tailor psychiatric drug development.

Updated on Sept. 29, 2026 in Mental Health

Bold flat-color editorial illustration featuring a glass vial and metallic sensor, symbolizing biomarker-guided medical research. — The American College of Neuropsychopharmacology has proposed a new framework utilizing biomarkers like blood and EEG data to refine psychiatric drug development and clinical trials. AI Illustration. Upload story photo >

Live Poll

Do you support using biological tests to help determine the best psychiatric medication for a patient?

The American College of Neuropsychopharmacology has released a position paper proposing the use of blood, brain activity, and wearable data to identify patient subgroups. This framework aims to move psychiatry away from costly trial-and-error prescribing methods.

Why it matters

Current psychiatric drug development often relies on time-consuming trials that lack precision. By integrating measurable biomarkers, researchers hope to improve clinical results and lower costs for both industry and payers.

The proposal was published in Volume 18, Issue 4 of the journal NPP - Digital Psychiatry and Neuroscience. Biomarker-guided methods are currently standard practice in oncology, cardiology, Alzheimer disease, and Parkinson disease care.

The players

American College of Neuropsychopharmacology

This professional organization is dedicated to the study of the brain and behavior in relation to pharmaceutical interventions.

UCLA Health

This academic health system collaborated as a lead representative on the task force that developed the new research roadmap.

National Institute of Mental Health

This federal agency contributed to the task force to help guide future psychiatric research and clinical standards.

FDA Office of Neuroscience

This regulatory division works to ensure that new drug development pathways meet scientific and safety requirements.

The details

Developed by the ACNP Precompetitive Stakeholder Task Force, the plan recommends utilizing blood tests, genetics, electroencephalography, and wearable device data. Success requires a new precompetitive framework that encourages data sharing and standardized collection across all research sites.

UCLA Health issued a related news release on September 18, 2026.
The position paper was published on September 29, 2026.

The Big Picture

The proposal follows the paradigm set by the clinical adoption of biomarker-guided treatment in oncology. This initiative seeks to replicate the success of precision medicine in cancer care by applying similar biological screening techniques to mental health trials.

If successfully implemented, these guidelines could lead to more effective medications with fewer trial-and-error cycles for patients. Future clinical trials may eventually provide more personalized treatment options based on an individuals specific biological profile.

The takeaway

The move toward biomarker-guided trials represents a significant shift toward precision psychiatry that mirrors advancements in other medical fields. Patients may eventually see a reduction in the time it takes to find an effective treatment for complex mental health conditions.